11th Mar 2008 07:00
Tepnel Life Sciences PLC11 March 2008 FOR IMMEDIATE RELEASE Tepnel Life Sciences launches biopharmaceutical and genotyping services at Livingston Manchester, U.K, 11 March 2008 Tepnel Life Sciences (AIM: TED), theinternational Molecular Diagnostics and Research Products & Services group,today announced the completion of Phase II construction and launch ofbiopharmaceutical and clinical genotyping services at its Livingston facility. Clinical genotyping is a growing area of genetic analysis with the potential tolead to personalised medicine. It works by linking a patient's genetic makeupto their response to particular drugs, enabling specialists to establish whichtreatments will best benefit an individual. Clinical genotyping also allows forthe early identification of genetic disease. The introduction of biopharmaceutical and genotyping services will give Tepnelaccess to these rapidly-growing markets, enabling the Company to offer completeservice packages to clients across these two broad areas. With these new capabilities, Tepnel will simultaneously increase the productdevelopment capabilities of its Molecular Diagnostics division and become one ofthe UK's leading providers to the pharmaceutical and molecular diagnosticssectors. Tepnel's Chief Executive Officer, Ben Matzilevich, said: "The completion of ourstate-of-the-art pharmaceutical testing facility in Livingston, Scotland willenable us to establish clinical genotyping and biopharmaceutical operations andexpand our small molecule pharmaceutical service capabilities. Thesecapabilities are key to our long term growth strategy. "We look forward to providing our pharmaceutical customers with a full line ofin-house services that increases efficiency, maintains sample integrity andminimises the risks associated with inter-laboratory transfer." Officially opened in September 2007, the £5 million Livingston pharmaceuticaltesting facility was part funded by Scottish Enterprise, Edinburgh and Lothian. -Ends- For further information: Tepnel Life Sciences plc Ben Matzilevich, CEO Carol Smith Tel: 0161 946 2200 Capital MS&L Mary Clark or Catie Corcoran Tel: +44 20 7307 5330 Seymour Pierce LimitedMark PercyTel: +44 20 7107 8000 Notes to Editors: About Tepnel Life Sciences plc - Tepnel Life Sciences plc (AIM: TED) is aUK-based international life sciences products and services group with twodivisions, Molecular Diagnostics and Research Products & Services. The Companyhas laboratories, manufacturing and operations in the USA, UK and France withover 200 employees. Tepnel provides test kits, reagents and services to two highly synergisticmarkets, these being Molecular Diagnostics and Biomedical Research. The Company's strategy has been to identify high growth niche opportunitieswithin these multi-billion pound markets. Tepnel focuses on these opportunitieswith internally developed products, patents, expertise and know-how as well asstrategic acquisitions, to develop a leadership position within these definedmarket segments. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
TED.L